Cardinal Health (CAH)
(Delayed Data from NYSE)
$103.81 USD
+0.27 (0.26%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $103.81 0.00 (0.00%) 7:22 PM ET
3-Hold of 5 3
A Value A Growth C Momentum A VGM
Price, Consensus and EPS Surprise
CAH 103.81 +0.27(0.26%)
Will CAH be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CAH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CAH
Assessing Super Micro Computer (SMCI) Ahead of Q3 Earnings
ETSY Gears Up to Report Q1 Earnings: What's in the Cards?
CAH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Amazon (AMZN) Stock Worth Buying Ahead of Q1 Earnings?
Cardinal Health (CAH) Reports Next Week: Wall Street Expects Earnings Growth
Paramount Global (PARA) to Report Q1 Earnings: What's in Store?
Other News for CAH
Cardinal Health handed FDA warning for marketing unapproved devices
Cardinal Health price target lowered to $110 from $118 at Evercore ISI
A Repeat of 2022? 7 Defensive Stocks to Buy Before the Correction.
Cardinal Health Faces Earnings Uncertainty Post OptumRx Contract Loss: Analyst Holds Rating
Maintaining a Buy Rating: Cardinal Health’s Strong Fundamentals and Growth Prospects Despite OptumRx Contract Loss